Prospects of a type 1 diabetes vaccine

References

• Weiner HL, da Cunha AP, Quintana F, et al. Oral tolerance. Immunol Rev. 2011;241:241–259. ​
   PubMed Web of Science ®Google Scholar
• Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American Diabetes Association. Diabetes Care. 2015;38:1964–1974. ​
   Web of Science ®Google Scholar
• Dotta F, Sebastiani G. Enteroviral infections and development of type 1 diabetes: the Brothers Karamazov within the CVBs. Diabetes. 2014;63:384–386.
   PubMed Web of Science ®Google Scholar
• Vaarala O, Knip M, Paronen J, et al. Cow’s milk formula feeding induces primary immunization to insulin in infants at genetic risk for type 1 diabetes. Diabetes. 1999;48:1389–1394.
   PubMed Web of Science ®Google Scholar
• Vaarala O, Atkinson MA, Neu J. The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes. 2008;57:2555–2562.
   PubMed Web of Science ®Google Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial–type 1. Diabetes Care. 2005;28:1068–1076.
   PubMed Web of Science ®Google Scholar
• Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus. [ cited 2017 Feb 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT00419562
   Google Scholar
• Bonifacio E, Ziegler A-G, Klingensmith G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes. Jama. 2015;313:1541.
   PubMed Web of Science ®Google Scholar
• Pre-POINT-Early Study. [ cited 2017 Feb 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02547519
   Google Scholar
• Raz I, Elias D, Avron A, et al. β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet. 2001;358:1749–1753.
   PubMed Web of Science ®Google Scholar
• Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378:319–327.
   PubMed Web of Science ®Google Scholar
• Thrower SL, James L, Hall W, et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study. Clin Exp Immunol. 2009;155:156–165.
   PubMed Web of Science ®Google Scholar
• Gibson VB, Nikolic T, Pearce VQ, et al. Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model. Clin Exp Immunol. 2015;182:251–260.
   PubMed Web of Science ®Google Scholar
• Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De). [ cited 2017 Feb 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02620332
   Google Scholar
• Roep BO, Solvason N, Gottlieb PA, et al. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci Transl Med. 2013;5:191ra82.
   PubMed Web of Science ®Google Scholar
• Tsai S, Shameli A, Yamanouchi J, et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity. 2010;32:568–580.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7:315ra189.
   PubMed Web of Science ®Google Scholar
• Suwandi JS, Toes REM, Nikolic T, et al. Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells. Clin Exp Rheumatol. 2015;33:S97–103.
   PubMed Web of Science ®Google Scholar
• Dunne JL, Overbergh L, Purcell AW, et al. Posttranslational modifications of proteins in type 1 diabetes: the next step in finding the cure? Diabetes. 2012;61:1907–1914.
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53:614–623.
   PubMed Web of Science ®Google Scholar
• Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients. [ cited 2017 Feb 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02000817
   Google Scholar
• Takiishi T, Korf H, Van Belle TL, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest. 2012;122:1717–1725.
   PubMed Web of Science ®Google Scholar
• Robert S, Gysemans C, Takiishi T, et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes. 2014;63:2876–2887.
   PubMed Web of Science ®Google Scholar
• Takiishi T, Cook DP, Korf H, et al. Reversal of diabetes in NOD mice by clinical-grade pro-insulin and IL10 secreting lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T cells. Diabetes. 2017;66:448–459.
   PubMed Web of Science ®Google Scholar
• Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:754–759.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-Lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361:2143–2152.
   PubMed Web of Science ®Google Scholar
• Yoon YM, Lewis JS, Carstens MR, et al. A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice. Sci Rep. 2015;5:13155.
   PubMed Web of Science ®Google Scholar
• Rosenzwajg M, Churlaud G, Mallone R, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015;58:48–58.
   PubMed Web of Science ®Google Scholar
• Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes. [ cited 2017 Feb 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02411253
   Google Scholar